Cesar A. Sanchez-Rodriguez - Publications

Effects of a 12-Week Supervised Exercise Program on Quality of Life, Functional Capacity, and Biological Parameters in Women with Breast Cancer: A Prospective Pilot Program.

Journal: Journal of clinical medicine

Published: January 18, 2026

Cross-Species and Tissue-Agnostic Prediction of Human Cancer Treatment Response using AI-Powered Cellular Morphometric Biomarkers from a Genetically Diverse Erbb2 Mouse Model.

Journal: medRxiv : the preprint server for health sciences

Published: September 26, 2025

Exercise in cancer patients: assistance levels and referral pathways-a position statement from the Spanish Society of Medical Oncology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 29, 2024

Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.

Journal: Future oncology (London, England)

Published: February 02, 2024

NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence.

Journal: Research square

Published: October 27, 2023

Late recurrence of lobular breast carcinoma presented as gastric metastasis.

Journal: Revista espanola de enfermedades digestivas

Published: October 26, 2023

NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence.

Journal: Clinical and translational medicine

Published: October 21, 2023

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk.

Journal: Cells

Published: April 17, 2023

Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk.

Journal: bioRxiv : the preprint server for biology

Published: January 30, 2023

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2- advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial.

Journal: Breast (Edinburgh, Scotland)

Published: July 21, 2022

Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.

Journal: Cancer research

Published: January 27, 2020

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer.

Journal: Journal of clinical medicine

Published: November 07, 2019